A rational approach to enhancing antibody Fc homodimer formation for robust production of antibody mixture in a single cell line

被引:2
作者
Yu, Jie [1 ,2 ]
Wang, Xiaoxiao [3 ]
Xu, Tao [3 ]
Jin, Qiuheng [1 ,2 ]
Duan, Jinyuan [1 ,2 ]
Wu, Jie [3 ]
Wu, Haiyan [3 ]
Xu, Ting [3 ]
Ye, Sheng [1 ,2 ]
机构
[1] Zhejiang Univ, Life Sci Inst, 866 Yuhang Tang Rd, Hangzhou 310058, Zhejiang, Peoples R China
[2] Zhejiang Univ, Innovat Ctr Cell Signaling Network, Hangzhou 310058, Zhejiang, Peoples R China
[3] Alphamab Co Ltd, Suzhou 215125, Peoples R China
基金
中国国家自然科学基金;
关键词
GROWTH-FACTOR RECEPTOR; HUMAN POLYCLONAL ANTIBODIES; THERAPEUTIC ANTIBODIES; MONOCLONAL-ANTIBODIES; ANTITUMOR-ACTIVITY; NEXT-GENERATION; BISPECIFIC IGG; CANCER; PHARMACOKINETICS; STRATEGIES;
D O I
10.1074/jbc.M116.771188
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Combinations of different antibodies have been shown to be more effective for managing certain diseases than monotherapy. Co-expression of the antibody mixture in a single cell line is key to reducing complexity during antibody development and manufacturing. However, co-transfection of multiple light and heavy chains into cells often leads to production of mismatched, heterodimeric by-products that are inactive, making the development of co-expression systems that robustly and efficiently produce highly active antibody mixtures a high priority. In this study, we modified the CH3 domain interface of the antibody fragment crystallizable (Fc) region by changing several charge pairs to create electrostatic interactions favoring Fc homodimer formation and disfavoring Fc heterodimer formation. When co-expressed, these modified antibodies with altered charge polarity across the Fc dimer interface preferentially formed homodimers that fully preserved the functions of each component, rather than inactive heterodimers whose formation was reduced because of rationally designed repulsive interactions. We designed eight different combinations and experimentally screened the best one, which enabled us to produce a binary antibody mixture against the EGF receptor with a minimal heterodimer contaminant. We further determined the crystal structure of a triple-mutated Fc variant in the best combination, and we elucidated the molecular interactions favoring Fc homodimer over heterodimer formation, which provided a structural basis for further optimization. The approach presented here demonstrates the feasibility of rational antibody modification for efficient and consistent production of monoclonal antibody mixtures in a single cell line and thus broadens our options for manufacturing more effective antibody-based therapeutic agents.
引用
收藏
页码:17885 / 17896
页数:12
相关论文
共 40 条
[1]  
[Anonymous], 2015, PYMOL MOL GRAPHICS S
[2]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[3]   CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast Cancer [J].
Baselga, Jose ;
Swain, Sandra M. .
CLINICAL BREAST CANCER, 2010, 10 (06) :489-491
[4]   Strategies and challenges for the next generation of therapeutic antibodies [J].
Beck, Alain ;
Wurch, Thierry ;
Bailly, Christian ;
Corvaia, Nathalie .
NATURE REVIEWS IMMUNOLOGY, 2010, 10 (05) :345-352
[5]   Passive antibody therapy for infectious diseases [J].
Casadevall, A ;
Dadachova, E ;
Pirofski, L .
NATURE REVIEWS MICROBIOLOGY, 2004, 2 (09) :695-703
[6]   Therapeutic antibodies for autoimmunity and inflammation [J].
Chan, Andrew C. ;
Carter, Paul J. .
NATURE REVIEWS IMMUNOLOGY, 2010, 10 (05) :301-316
[7]   Generation of Stable Cell Clones Expressing Mixtures of Human Antibodies [J].
de Kruif, John ;
Kramer, Arjen ;
Nijhuis, Roy ;
van der Zande, Vanessa ;
den Blanken, Renate ;
Clements, Carina ;
Visser, Therese ;
Keehnen, Rob ;
den Hartog, Marcel ;
Throsby, Mark ;
Logtenberg, Ton .
BIOTECHNOLOGY AND BIOENGINEERING, 2010, 106 (05) :741-750
[8]   Convergent solutions to binding at a protein-protein interface [J].
DeLano, WL ;
Ultsch, MH ;
de Vos, AM ;
Wells, JA .
SCIENCE, 2000, 287 (5456) :1279-1283
[9]   Emerging antibody combinations in oncology [J].
Demarest, Stephen J. ;
Hariharan, Kandasamy ;
Dong, Jianying .
MABS, 2011, 3 (04) :338-351
[10]   The therapeutic monoclonal antibody market [J].
Ecker, Dawn M. ;
Jones, Susan Dana ;
Levine, Howard L. .
MABS, 2015, 7 (01) :9-14